HepatoChem will be attending the New Jersey Drug Metabolism Discussion Group Spring Symposium on May 1, 2014 at The Palace at Somerset Park in Somerset, NJ. Be sure to visit us to hear about our latest technologies!
HepatoChem has developed extensive capabilities to quickly survey organo-metallic chemistry systems and design innovative tools for the pharmaceutical industry. It has most recently commercialized the BMO (BioMimetic Oxidation) Kit, which utilizes rapid one step biomimetic chemistry to generate useful quantities of drug candidate metabolites. Applying a similar developmental approach, HepatoChem is now providing unique tools for the instant and flexible diversification of biologically active small molecules. These tools are largely centered on fluorination chemistry. HepatoChem is currently working with Vertex, a local biotech based in Boston, MA, to develop tools to allow for fast discovery of fluorinated analogues of small molecules, which Vertex scientists will employ in their own projects.
HepatoChem Co-founder and President Marc Bazin stated “Our work with Vertex is an extraordinary opportunity to demonstrate the versatility of HepatoChem’s platform. We are all committed to the development of innovative tools, such as chemical diversification kits, for companies that are seeking to discover and develop new medicines. “
About HepatoChem, Inc.
Founded in 2008, HepatoChem is an early-stage company that offers innovative services and products to the pharmaceutical industry. Our core expertise is organo-metallic catalysis and high-throughput compound analysis. HepatoChem received the Accelerator Loan from Mass Life Sciences Center in 2012 and is located in Beverly, MA at NorthShore InnoVentures (NSIV).
100 Cummings Center, Suite 424J
Beverly, MA 01915
Phone: (617) 500-5285
Fax: (617) 274-0827
HepatoChem is mentioned in a recent Bioorganic & Medicinal Chemistry Letters Digest article entitled, ‘Emerging technologies for metabolite generation and structural diversification‘. Be sure to check out the article at www.sciencedirect.com !
Cusack, Kevin P.; Vasudevan, Anil. Emerging technologies for metabolite generation and structural diversification. Bioorganic & Medicinal Chemistry Letters 23, 2013, 5471–5483.
HepatoChem will be attending The 10th International ISSX Meeting in Toronto from September 29th to October 2nd to unveil our new BMO Kit. Be sure to stop by and visit us at booth 505!
In Salem News
BEVERLY — Early stage life sciences and “cleantech” companies that are part of the nonprofit business incubator North Shore InnoVentures are benefiting not only from reduced rates for lab and office space, but from the advice and networking it offers.
“To be successful, you can’t do it yourself,” said AdvaStim co-founder and Chief Technology Officer Barry Yomtov, whose medical device startup was one of the first to join North Shore InnoVentures.
“Networking is the biggest part,” said Martha Farmer, president and CEO of North Shore InnoVentures.
The 2nd Mitigation Strategies for Reactive Metabolites is the only meeting dedicated to helping you implement more effective risk assessment strategies for reactive metabolites in your organization and truly minimize the attrition of your pipeline.
November 27-29, 2012 at Revere Hotel, Boston, MA
HepatoChem will be present at the ISSX North American meeting on October 14th-18th in Dallas, Texas, USA.
Please come to visit us at the booth 113
HepatoChem and NSIV Meets the Governor of MA May 30th at Cummings Park in Beverly. The Salem News references HepatoChem and NSIV in an article referencing the visit of Governor Deval Patrick of Massachusetts on May 30th to Cummings Park complex in Beverly where he honor both their commitment to green energy and life science industries. Click here to read the full article.